Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors

Mixed ductal‐endocrine carcinoma derived from intraductal papillary mucinous neoplasm (IPMN) of the pancreas identified by human telomerase reverse transcriptase (hTERT) expression

“…Although the endocrine component showed a Ki-67 proliferation index of less than 2%, hTERT was up-regulated during the progression of the tumor, predicting its unfavorable behavior [13]. Moreover, the majority of the tumor cells were positive for MUC1, HGM, pS2, and SIMA, which are associated with an adverse prognosis and a high tendency to metastasize [18,25,26].…”

What Is Recent in Pancreatic Cancer Immunotherapy?

“…MUC1 (mucin-1, CD227) is a polymorphic, glycosylated type I transmembrane protein present in glandular epithelium of different tissues (pancreas, breast, lung) and overexpressed (aberrantly glycosylated) in 90% of pancreatic cancers [36, 37]. It inhibits cell-cell and cell-stroma interactions and functions as a signal transducer in the cancer progression, including tumor invasion and metastasis [38].…”

Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells

“…The factors include those involved in VEGF (Seo et al 2000), EGF (Bloomston et al 2006), Notch (Doucas et al 2008), IGF (Hakam et al 2003), MUC (Yamasaki et al 2004), K-Ras (Almoguera et al 1988), PI3 K-AKT (Asano et al 2004), and sonic hedgehog (Thayer et al 2003) signaling pathways. Importantly, the factors in the Ras-MAPK, PI3K-AKT-mTOR, and Hedgehog pathways were reported to be the most important ones that contribute to invasion and metastasis of pancreatic cancer.…”